Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interactions of Artemether-lumefantrine, Amodiaquine and Primaquine
NCT02696954Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of artemether + lumefantrine, amodiaquine and primaquine in malaria (2 arms), sponsored by University of Oxford. Primary endpoints: Area under the concentration-time curve (AUC (0-infinity)) at 1 year, Area under the concentration-time curve (AUC (0-last)) at 1 year and 1 more. Started Nov 2016; status: terminated.
02
Drugs
artemether + lumefantrineamodiaquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02696954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696954.